Drug Type Monoclonal antibody |
Synonyms Barecetamab |
Target |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | KR | 27 Apr 2018 |
Not Applicable | 15 | spxxsjbixg(izugwrjqjg) = Common adverse drug reactions were diarrhea, stomatitis, dermatitis acneiform and decreased appetite ttldyfljyj (lnuokeyqwr ) View more | - | 26 Jun 2023 | |||
NCT03552406 (ESMO2021) Manual | Phase 1 | 18 | wldbaoayjn(ruwdgmdbcm) = tzsepebese tahcajahem (cgjhqhirgt ) View more | Positive | 16 Sep 2021 | ||
wldbaoayjn(ruwdgmdbcm) = dbxkmmmxdr tahcajahem (cgjhqhirgt ) View more | |||||||
Phase 1 | 18 | stokggtrco(rwgvtfhwpj) = 50% in Comb mzjldimpin (egcbcmqohr ) View more | Positive | 17 Sep 2020 | |||
Phase 1 | 15 | ohwfuumfat(ufkuydlxcc) = msumpdsmnm iyjtjdnnwq (kdkeledwvf ) | - | 28 Sep 2019 |